ConductScience.org, home

Paper42948745PubMed

Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis.

He Z and 15 others. Acta Pharm Sin B, 2026.

Cite this record

ConductScience Library. Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis. Papers, record 42948745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42948745

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis.
Journal
Acta Pharm Sin B
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-29

Source PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1He ZZhongshan
2Luo YYaoyao
3Li YYongjiang
4Yang SShuping
5Fan YYingjun
6Zhang YYi
7Liu SShengbin
8Zhou ZZhuoming
9Cao CChengjian
10Shi HHaixing
11Guo MMengran
12Chen YYuting
13Zhang YYupei
14Qin DDuotian
15Chen WWei
16Song XXiangrong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120080636Resolvin D1 binds human phagocytes with evidence for proresolving receptors.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20080636PubMed
231222041Resolvin D1 promotes the targeting and clearance of necroptotic cells.Cell Death Differ2020https://conductscience.org/library/papers/31222041PubMed
341494534Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.Cell Rep Med2026https://conductscience.org/library/papers/41494534PubMed
427437576CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.Nature2016https://conductscience.org/library/papers/27437576PubMed
532865380Colchicine in Patients with Chronic Coronary Disease.N Engl J Med2020https://conductscience.org/library/papers/32865380PubMed
635678191Theranostic Contribution of Extracellular Matrix Metalloprotease Inducer-Paramagnetic Nanoparticles Against Acute Myocardial Infarction in a Pig Model of Coronary Ischemia-Reperfusion.Circ Cardiovasc Imaging2022https://conductscience.org/library/papers/35678191PubMed
730846875Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities.Nat Rev Cardiol2019https://conductscience.org/library/papers/30846875PubMed
839501093Nanomedicine-based strategies for the treatment of vein graft disease.Nat Rev Cardiol2025https://conductscience.org/library/papers/39501093PubMed
934759324Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.Nat Rev Cardiol2022https://conductscience.org/library/papers/34759324PubMed
1026284535Ultrathin Black Phosphorus Nanosheets for Efficient Singlet Oxygen Generation.J Am Chem Soc2015https://conductscience.org/library/papers/26284535PubMed
1133472399Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation.Arterioscler Thromb Vasc Biol2021https://conductscience.org/library/papers/33472399PubMed
1237607320Natural Antioxidant-Based Nanodrug for Atherosclerosis Treatment.Small2023https://conductscience.org/library/papers/37607320PubMed
138610116Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages.Proc Natl Acad Sci U S A1996https://conductscience.org/library/papers/8610116PubMed
1420133865Spatiotemporal controlled delivery of nanoparticles to injured vasculature.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20133865PubMed
1531822793Efferocytosis in health and disease.Nat Rev Immunol2020https://conductscience.org/library/papers/31822793PubMed
1632718990siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.Sci Transl Med2020https://conductscience.org/library/papers/32718990PubMed
1730380386CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.N Engl J Med2018https://conductscience.org/library/papers/30380386PubMed
1841250788Multifunctional Inorganic-Nanosheets-Based Nanohydrogel for Periodontal Bone Regeneration via Antibacterial and Anti-Ferroptotic Immunomodulation.ACS Appl Mater Interfaces2025https://conductscience.org/library/papers/41250788PubMed
1932004476Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury.Cell Metab2020https://conductscience.org/library/papers/32004476PubMed
2032714754Photochemical Activity of Black Phosphorus for Near-Infrared Light Controlled In Situ Biomineralization.Adv Sci (Weinh)2020https://conductscience.org/library/papers/32714754PubMed

See all 49 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42948745

GET https://conductscience.org/api/papers/v1/42948745/references?page=2